Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma

Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma

Abstract Background In renal cell carcinoma (RCC), no clinically available biomarker has been utilized for checkpoint inhibitor immunotherapy (IO) + tyrosine kinase inhibitor (TKI) combinations. Galectin‐1 overexpression is found in tumors, with potential immune‐regulating roles. Methods RNA‐sequenc...

Full description

Bibliographic Details
Main Authors: Jiajun Wang, Sihong Zhang, Ying Wang, Yanjun Zhu, Xianglai Xu, Jianming Guo
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Cancer Medicine
Subjects:
galectin‐1
immune checkpoint inhibitor
renal cell carcinoma
T cell exhaustion
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.7113

Internet

https://doi.org/10.1002/cam4.7113

Similar Items